# US 2012/0083517 A1 · Polymorphs of saxagliptin hydrochloride and processes for preparing them

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0083517 A1
- Document ID: US20120083517A1
- Status: Published application
- Kind: A1
- Application number: 13/252,682
- Filed: 2011-10-04
- Published: 2012-04-05
- Earliest claimed: 2010-10-04
- Assignees: Teva Pharmaceutical Industries Ltd.
- Inventors: Marina Marinkovic; Marina Ratkaj; Oliver Frankovic; Tina Mundorfer
- Web page: https://patentgrep.com/patent/US20120083517A1

## CPC

- C07D 209/52: condensed with a ring other than six-membered
- A61K 31/403: condensed with carbocyclic rings, e.g. carbazole
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/08: for glucose homeostasis (pancreatic hormones A61P5/48)
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention provides polymorphs of Saxagliptin hydrochloride, processes for preparing polymorphs of Saxagliptin hydrochloride, and pharmaceutical compositions of polymorphs of Saxagliptin hydrochloride.

## Claims

### Claim 1

Crystalline Saxagliptin hydrochloride Form K.

### Claim 2 (depends on 1)

The crystalline Saxagliptin hydrochloride Form K of claim 1, characterized by data selected from: a powder XRD pattern having peaks at 6.4, 11.4, 12.8, 15.7, and 19.4 degrees 2-theta±0.2 degrees 2-theta; an X-ray powder diffraction pattern substantially as depicted in FIG. 16; a solid-state 13C NMR spectrum having characteristic peaks at 167.0, 120.2, 58.8, 45.3 and 30.5 ppm±0.2 ppm; a solid-state 13C NMR spectrum substantially as depicted in FIG. 19; and combinations thereof.

### Claim 3 (depends on 1)

The crystalline Saxagliptin hydrochloride Form K of claim 1, characterized by a powder XRD pattern having peaks at 6.4, 11.4, 12.8, 15.7, and 19.4 degrees 2-theta±0.2 degrees 2-theta.

### Claim 4 (depends on 3)

The crystalline Saxagliptin hydrochloride Form K of claim 3, further characterized by additional powder XRD peaks at 5.4, 14.8, 16.7, and 22.1 degrees 2-theta±0.2 degrees 2-theta.

### Claim 5 (depends on 3)

The crystalline Saxagliptin hydrochloride Form K of claim 3, further characterized by one, two, three, or four additional powder XRD peaks selected from 5.4, 14.8, 16.7, and 22.1 degrees two theta±0.2 degrees two theta.

### Claim 6

Crystalline Saxagliptin hydrochloride Form Z.

### Claim 7 (depends on 6)

The crystalline Saxagliptin hydrochloride Form Z of claim 6, characterized by data selected from: an X-ray powder diffraction pattern having peaks at 9.3, 12.0, 14.2 and 19.2 degrees two theta±0.2 degrees two theta; an X-ray powder diffraction pattern substantially as depicted in FIG. 18; a solid-state 13C NMR spectrum having characteristic peaks at 46.5, 44.9, 42.5 and 29.1 ppm, ±0.1 ppm; a solid-state 13C NMR spectrum substantially as depicted in any one of FIGS. 20-21; and combinations thereof.

### Claim 8 (depends on 6)

The crystalline Saxagliptin hydrochloride Form Z of claim 6, characterized by an X-ray powder diffraction pattern having peaks at 9.3, 12.0, 14.2 and 19.2 degrees two theta±0.2 degrees two theta.

### Claim 9 (depends on 8)

The crystalline Saxagliptin hydrochloride Form Z of claim 8, further characterized by additional X-ray powder diffraction peaks at 8.1, 16.6 and 23.2 degrees two theta±0.2 degrees two theta.

### Claim 10

Crystalline Saxagliptin hydrochloride Form D.

### Claim 11 (depends on 10)

The crystalline Saxagliptin hydrochloride Form D of claim 10, characterized by data selected from: an X-ray powder diffraction pattern having peaks at 10.6, 14.4, 15.4, 17.3, 22.6 and 25.7 degrees two theta±0.2 degrees two theta; an X-ray powder diffraction pattern substantially as depicted in FIG. 11; and combinations thereof; a solid-state 13C NMR spectrum having characteristic peaks at 46.2, 44.8, 42.3, 32.1 and 14.7 ppm, ±0.1 ppm; a solid-state 13C NMR spectrum substantially as depicted in any one of FIGS. 22-23.

### Claim 12 (depends on 10)

The crystalline Saxagliptin hydrochloride Form D of claim 10, characterized by a powder XRD pattern having peaks at 10.6, 14.4, 15.4, 17.3, 22.6 and 25.7 degrees 2-theta±0.2 degrees 2-theta.

### Claim 13 (depends on 12)

The crystalline Saxagliptin hydrochloride Form D of claim 12, further characterized by an X-ray powder diffraction pattern having peaks at 8.6 and 19.0 degrees two theta±0.2 degrees two theta.

### Claim 14

Amorphous Saxagliptin hydrochloride.

### Claim 15 (depends on 14)

The amorphous Saxagliptin hydrochloride of claim 14, characterized by an X-ray powder diffraction pattern substantially as depicted in FIG. 17.

### Claim 16 (depends on 1, 6, 10, 14)

A process of preparing a Saxagliptin hydrochloride solid state form selected from: monohydrate form H-1, hemihydrate form H0.5-2, dihydrate forrrl H2-1, anhydrous form N-3 or any mixture thereof, said process comprising converting the solid state form of Saxagliptin hydrochloride according to any one of claim 1, 6, 10 or 14 to said solid state form selected from: monohydrate form H-1, hemihydrate form H0.5-2, dihydrate form H2-1, anhydrous form N-3 or mixture thereof.

### Claim 17 (depends on 1, 6, 10, 14)

A pharmaceutical composition comprising a solid state form of Saxagliptin hydrochloride according to any one of claim 1, 6, 10 or 14; or any combination of said solid state forms, and at least one pharmaceutically acceptable excipient.

### Claim 18 (depends on 17)

A method of treating a patient suffering from type 2 diabetes, comprising administering a pharmaceutical composition according to claim 17.
